TRASTUZUMAB PACKAGE INSERT - AN OVERVIEW

Among the most underneath-investigated “driving forces” linked to trastuzumab resistance is PTEN. Nagata et al. (2004) described that the loss of PTEN was observed in 36% of HER2-favourable Principal breast tumor specimens from patients with phase IV condition. In addition, In addition they confirmed that sufferers with PTEN-deficient tumors ex